Matching articles for "female sexual dysfunction"

Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder

   
The Medical Letter on Drugs and Therapeutics • July 29, 2019;  (Issue 1577)
The FDA has approved bremelanotide (Vyleesi – Amag), a melanocortin receptor agonist, for subcutaneous treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder...
The FDA has approved bremelanotide (Vyleesi – Amag), a melanocortin receptor agonist, for subcutaneous treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Bremelanotide is not approved for use in men or postmenopausal women. It is the second drug to be approved in the US for this indication; flibanserin (Addyi), which was approved in 2015, was the first.
Med Lett Drugs Ther. 2019 Jul 29;61(1577):114-6 | Show Full IntroductionHide Full Introduction

Imvexxy - Another Estradiol Vaginal Insert for Dyspareunia

   
The Medical Letter on Drugs and Therapeutics • September 10, 2018;  (Issue 1555)
The FDA has approved an estradiol softgel vaginal insert (Imvexxy – TherapeuticsMD) for treatment of postmenopausal women with moderate to severe dyspareunia due to vulvovaginal atrophy (VVA). Imvexxy is...
The FDA has approved an estradiol softgel vaginal insert (Imvexxy – TherapeuticsMD) for treatment of postmenopausal women with moderate to severe dyspareunia due to vulvovaginal atrophy (VVA). Imvexxy is the second estradiol vaginal insert to be approved in the US; Vagifem, an intravaginal tablet formulation, was the first. Vagifem and Imvexxy are both available in inserts containing 10 mcg of estradiol; Imvexxy is also available in a 4-mcg strength.
Med Lett Drugs Ther. 2018 Sep 10;60(1555):147-8 | Show Full IntroductionHide Full Introduction

Prasterone (Intrarosa) for Dyspareunia

   
The Medical Letter on Drugs and Therapeutics • September 11, 2017;  (Issue 1529)
The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA). Also called...
The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA). Also called dehydroepiandrosterone (DHEA), prasterone is produced in the adrenal glands, gonads, and brain and converted intracellularly into active metabolites of estrogens and androgens. DHEA has been available over the counter for years as an oral dietary supplement claimed to benefit sexual, cardiovascular, and neuropsychiatric dysfunction.
Med Lett Drugs Ther. 2017 Sep 11;59(1529):149-50 | Show Full IntroductionHide Full Introduction

Addendum: Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder

   
The Medical Letter on Drugs and Therapeutics • November 9, 2015;  (Issue 1481)
When our article on flibanserin (Addyi) was published (Med Lett Drugs Ther 2015; 57:133), the drug had not yet been marketed. Flibanserin became available on October 17, 2015 at a cost of $800 for a 30-day...
When our article on flibanserin (Addyi) was published (Med Lett Drugs Ther 2015; 57:133), the drug had not yet been marketed. Flibanserin became available on October 17, 2015 at a cost of $800 for a 30-day supply.
Med Lett Drugs Ther. 2015 Nov 9;57(1481):156 | Show Full IntroductionHide Full Introduction

Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder

   
The Medical Letter on Drugs and Therapeutics • September 28, 2015;  (Issue 1478)
The FDA has approved flibanserin (Addyi – Sprout) for treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) not caused by another medical or...
The FDA has approved flibanserin (Addyi – Sprout) for treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) not caused by another medical or psychiatric condition, the effects of another drug, or relationship difficulties. Flibanserin is the first drug to be approved for treatment of HSDD. It is not approved for use in men or postmenopausal women. Previous FDA reviews of flibanserin in 2010 and 2013 did not result in approval.
Med Lett Drugs Ther. 2015 Sep 28;57(1478):133-5 | Show Full IntroductionHide Full Introduction

Drugs for Female Sexual Dysfunction

   
The Medical Letter on Drugs and Therapeutics • December 13, 2010;  (Issue 1353)
Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become...
Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.
Med Lett Drugs Ther. 2010 Dec 13;52(1353):100-2 | Show Full IntroductionHide Full Introduction

Drugs for Female Sexual Dysfunction

   
The Medical Letter on Drugs and Therapeutics • April 23, 2007;  (Issue 1259)
Sexual complaints related to desire, arousal, orgasm and pain are common in women. No drugs are approved by the FDA for any of these indications, but many are used...
Sexual complaints related to desire, arousal, orgasm and pain are common in women. No drugs are approved by the FDA for any of these indications, but many are used off-label.
Med Lett Drugs Ther. 2007 Apr 23;49(1259):33-5 | Show Full IntroductionHide Full Introduction